TW202203970A - 靶向冠狀病毒的IgY免疫球蛋白、其製備方法、及其使用方法 - Google Patents

靶向冠狀病毒的IgY免疫球蛋白、其製備方法、及其使用方法 Download PDF

Info

Publication number
TW202203970A
TW202203970A TW110112995A TW110112995A TW202203970A TW 202203970 A TW202203970 A TW 202203970A TW 110112995 A TW110112995 A TW 110112995A TW 110112995 A TW110112995 A TW 110112995A TW 202203970 A TW202203970 A TW 202203970A
Authority
TW
Taiwan
Prior art keywords
coronavirus
composition
administered
egg
individual
Prior art date
Application number
TW110112995A
Other languages
English (en)
Chinese (zh)
Inventor
桓胡 尼桂恩
特里 Ｎ 戴克
Original Assignee
加拿大商Ｉｇｙ免疫科技生命科學公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 加拿大商Ｉｇｙ免疫科技生命科學公司 filed Critical 加拿大商Ｉｇｙ免疫科技生命科學公司
Publication of TW202203970A publication Critical patent/TW202203970A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10241—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW110112995A 2020-04-10 2021-04-12 靶向冠狀病毒的IgY免疫球蛋白、其製備方法、及其使用方法 TW202203970A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063008298P 2020-04-10 2020-04-10
US63/008,298 2020-04-10
PCT/IB2021/052977 WO2021205408A1 (fr) 2020-04-10 2021-04-09 Immunoglobulines igy ciblant le coronavirus, procédés pour les préparer, et procédés les utilisant
WOPCT/IB2021/052977 2021-04-09

Publications (1)

Publication Number Publication Date
TW202203970A true TW202203970A (zh) 2022-02-01

Family

ID=78024002

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110112995A TW202203970A (zh) 2020-04-10 2021-04-12 靶向冠狀病毒的IgY免疫球蛋白、其製備方法、及其使用方法

Country Status (2)

Country Link
TW (1) TW202203970A (fr)
WO (1) WO2021205408A1 (fr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001088162A2 (fr) * 2000-05-16 2001-11-22 Genway Biotech, Inc. Procedes et vecteurs destines a generer des anticorps dans des especes aviaires et utilisations
CN1268643C (zh) * 2003-11-25 2006-08-09 中国人民解放军军事医学科学院微生物流行病研究所 一种抗SARS－CoV IgY抗体及其制备方法
US8106170B2 (en) * 2004-11-11 2012-01-31 Crucell Holland B.V. Compositions against SARS-coronavirus and uses thereof
MY164281A (en) * 2010-11-23 2017-11-30 Pantheryx Inc Compositions and methods for treatment in broad-spectrum, undifferentiated or mixed clinical applications
WO2016138160A1 (fr) * 2015-02-24 2016-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogènes du coronavirus du syndrome respiratoire du moyen-orient, anticorps et leur utilisation
CN112094341B (zh) * 2020-09-10 2021-05-18 华瑞同康生物技术（深圳）有限公司 抗新型冠状病毒的IgY中和抗体及其制备方法、制剂和应用
CN112279912A (zh) * 2020-11-10 2021-01-29 桂林医学院 新型冠状病毒禽蛋抗体SARS-CoV-2-IgY制剂及其制备方法与应用

Also Published As

Publication number Publication date
WO2021205408A1 (fr) 2021-10-14

Similar Documents

Publication Publication Date Title
EP2184067B1 (fr) Compositions de vaccin ADN pour le syndrome respiratoire aigu grave et procédés d'utilisation
WO2020063370A2 (fr) Composition immunitaire, son procédé de préparation et application associée
CN116023510B (zh) 双佐剂重组带状疱疹疫苗
TWI620574B (zh) 口蹄疫合成胜肽緊急疫苗
JP6532407B2 (ja) アイメリアに対する免疫応答を強化するか又はアイメリア感染症を制限する組成物及び方法
JP6530742B2 (ja) 腸内病原体の免疫応答を強化する組成物及び方法
CN113454102A (zh) 非洲猪瘟疫苗
CA2787661A1 (fr) Vecteurs de vaccin et procedes d'amplification de reponses immunitaires
CN116041544A (zh) 二价新冠疫苗及其制备方法及用途
TW202229314A (zh) 用於針對輪狀病毒疫苗接種之融合蛋白質
JP4382163B2 (ja) ターゲッティング分子を用いた免疫応答の増強
KR102675880B1 (ko) SARS-CoV-2 스파이크 단백질 및 면역글로불린의 Fc 유래 단백질을 포함하는 재조합 단백질 및 이의 용도
CN109369809B (zh) 多表位抗原及其制备方法与在制备防治鹦鹉热衣原体感染的药物中的应用
TW202203970A (zh) 靶向冠狀病毒的IgY免疫球蛋白、其製備方法、及其使用方法
KR102675879B1 (ko) SARS-CoV-2 스파이크 단백질 S1 유래 단백질 및 페리틴 유래 단백질을 포함하는 재조합 단백질 및 이의 용도
KR102675881B1 (ko) Pedv 스파이크 단백질 s1 유래 단백질 및 페리틴 유래 단백질을 포함하는 재조합 단백질 및 이의 용도
CN118356486A (zh) CpG佐剂在制备新型冠状病毒疫苗中的应用
TW202126328A (zh) 靶向非洲豬瘟病毒之疫苗與免疫球蛋白、製備其等之方法、及使用其等之方法
KR20230173115A (ko) 아프리카 돼지열 바이러스를 표적화하는 백신 및 이뮤노글로불린, 그의 제조 방법, 및 그의 사용 방법
US11623945B2 (en) Immunostimulating compositions and uses therefore
WO2022000845A1 (fr) Vaccin à base de protéine recombinée pour la prévention du sars-cov-2 et son procédé de préparation
US20240189418A1 (en) Virus vaccine based on virus surface engineering providing increased immunity
KR20240054479A (ko) 바이러스 표면 엔지니어링 기반의 면역 증강된 돼지 유행성 설사병 바이러스 백신
US20220280636A1 (en) Antigenic glycoprotein e polypeptides, compositions, and methods of use thereof
KR20240175004A (ko) Pedv 스파이크 단백질 s1 및 페리틴 유래 단백질을 포함하는 재조합 단백질 및 이의 용도